Richard P. Eno has served as President, Chief Executive Officer and Director since March 2008. Mr. Eno has more than twenty five years of professional experience in the chemicals and energy business. Prior to joining Metabolix, Mr. Eno served as Vice President, Leader Global Oil & Gas Sector at CRA International, a leading provider of management consulting services and economic and financial expertise to global companies. Earlier in his career, he held various roles at Arthur D. Little and Chevron Corporation. Mr. Eno holds a Bachelor of Science Degree in Chemical Engineering from Cornell University, a Masters in Business Administration from the University of Houston and is a Chartered Financial Analyst.
Chief Scientific Officer, Vice President, Research Oliver P. Peoples, Ph.D., a co-founder of Metabolix, has served as our chief scientific officer and vice president of research since January 2000, and was previously our director of research and vice president. Dr. Peoples has served as a director since June 1992. Prior to founding Metabolix, Dr. Peoples was a research scientist with the Department of Biology at the Massachusetts Institute of Technology where he emerged as a pioneer of the new field of metabolic pathway engineering and its applications in industrial biotechnology. The research carried out by Dr. Peoples at MIT established the fundamental tools and methods for engineering bacteria and plants to produce Mirel. Dr. Peoples has published numerous peer reviewed academic papers and is an inventor of over 90 patents and patent applications worldwide. Dr. Peoples received a Ph.D. in Molecular Biology from the University of Aberdeen, Scotland.
Sarah P. Cecil has served as legal counsel to Metabolix since July 2005 and as general counsel since the Company's initial public offering in November 2006. Previously she was corporate counsel at Vertex Pharmaceuticals from 1992 until 2001, and at Biogen from 1985 until 1991. Ms. Cecil's legal practice has also included clients in the food ingredients, computer services and clinical research industries, as well as several biotechnology companies. Ms. Cecil received an A.B. from Brown University, and she was a C.P.A. with Price Waterhouse before obtaining a J.D. from Harvard Law School.
Joseph Hill has been our Chief Financial Officer since April 2008. Mr. Hill has more than twenty years of professional experience in finance, including more than fifteen years of experience at the executive level. Prior to joining Metabolix, Mr. Hill served as Senior Vice President, Chief Financial Officer at Amicas, Inc., the leading independent provider of radiology image and information management solutions. At Amicas, Mr. Hill was responsible for all finance, accounting, investor relations, treasury, tax, administration, IT and infrastructure. Prior to that, he was vice president and CFO at Dirig Software, a privately held provider of application performance management software systems. And Mr. Hill previously served as vice president, CFO and Director of Maconomy, a publicly traded provider of web-based business management solutions with more than 70,000 users worldwide. In this role, Hill was responsible for all finance, accounting, treasury, tax, administration, and infrastructure of this public company with offices in eight countries. Mr. Hill has a B.S. in Business Administration from Bryant College and a M.S.F. from Bentley College.
Robert Engle, Vice President, Business and Commercial Development, Biopolymers joined the Company in 2009. He spent ten years with Ticona, the engineering polymers business of Celanese Corporation, where he served as Global Business Director. In addition as Ticona VP of Affiliate Management, he has served on the Boards of Directors of several international JVs, including Polyplastics, Korea Engineering Plastics and Fortron Industries. Prior to his experience at Ticona, Mr. Engle worked in corporate planning at Hoechst A.G. and in a chemicals and plastics consulting role at Arthur D. Little. Mr. Engle received a master's degree in Arabic focused on international business administration from Georgetown University and holds a bachelor's degree in Chemical Engineering from the University of Colorado.
Johan van Walsem, Vice President of Manufacturing and Product Development, has more than 20 years experience in the processing industry, with more than 15 years' experience leading development and manufacturing efforts for large scale fermentation-based processes. Mr. van Walsem returned to Metabolix in 2009, following a 16 month period as Senior Vice President, R&D and Bioprocessing at Joule Biotechnologies, a clean technology start-up in Cambridge. In his earlier role as Vice President Manufacturing, Development and Operations at Metabolix, Mr. van Walsem was integral in the technical development and business model design for Mirel, a biobased, biodegradable polymer now being commercialized through Telles. Mr. van Walsem received a Masters in Chemical Engineering from the University of Pretoria in 1986 and a MBA from the University of South Africa in 1995. He is a registered professional engineer with the Engineering Council of South Africa and a member of AIChE (American Institute of Chemical Engineers).
Max Senechal , Vice President, Biobased Chemicals, has more than 20 years of experience in the chemicals industry in both consulting and engineering. Mr. Senechal joined Metabolix in 2010 as director of strategy and commercial development, focused on the strategic direction and commercialization path for the Company's biobased industrial chemicals platform. From 2000 to 2010, Mr. Senechal served as a vice president for the chemicals & petroleum and life sciences practices at Charles River Associates International (CRA). At CRA, he focused on the development of business strategies, operations improvement projects, and due-diligence engagements. From 1995 to 2000, Mr. Senechal was a senior manager at Arthur D. Little, where he was responsible for a wide range of consulting assignments for leading chemical companies across the globe. Prior to his consulting career, Mr. Senechal was a project engineer where he supervised the design, construction and start-up of industrial facilities in several industries including commodity, specialty, and fine chemicals, and pharmaceuticals. Mr. Senechal earned his MBA from the University of Massachusetts School of Management, Boston, and his B.S. in mechanical engineering from Laval University, Quebec, Canada.
Lynne H. Brum has served as our Vice President of Marketing and Corporate Communications since November 2011. Ms. Brum has more than twenty years professional experience in communications for innovative, technology-based life science companies. Prior to joining Metabolix, Ms. Brum served as Executive Vice President at Porter Novelli Life Sciences, a leading public relations firm. Prior to that, Ms. Brum served as Vice President, Strategic Communications at Vertex Pharmaceuticals, Inc. where she was responsible for Corporate Communications, Investor Relations and Brand Management. Ms. Brum holds a bachelor's degree in biological sciences from Wellesley College and a master's degree in business administration from the Simmons Graduate School of Management.